Tencent Music Entertainment Group - ADR (TME) Stock Price Today
Aura AI Summary
Key Stats
- $15.16BMarket Cap
- 8,130,809Volume
- MediaSector
- $19.0152W High
- $7.7452W Low
- 71 DaysTypical Hold Time
- $13.09BEnterprise Value
- 2.6%Div Yield
- 100% Sell | 0% BuyTrading Activity
Track Tencent Music Entertainment Group - ADR (TME) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Tencent Music Entertainment Group - ADR has traded between a low of $7.74 and a high of $19.01, highlighting its annual price range. Buy and sell Tencent Music Entertainment Group - ADR shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Most Recent News
ASUS launches AI-ready hardware and software for gamers, creators, and enterprises with local, cloud, and hybrid AI options.
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...

Cosmetic peptide synthesis market to reach $355M by 2032, driven by anti-aging skincare demand and tech advances.
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...

Over 100 BCMA-targeted therapies in development are driving innovation in multiple myeloma treatment.
DelveInsight's 2026 report highlights more than 100 BCMA-targeted therapies in various clinical stages, focusing on multiple myeloma and other diseases. Leading pharma companies like Pfizer, Regeneron, and AstraZeneca are advancing treatments includi...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.